Janssen: New Data from MajesTEC-1 Study Show Continued Deep and Durable Responses of Teclistamab (BCMAxCD3 Bispecific Antibody) in Treatment of Heavily Pre-treated Patients with Multiple Myeloma

Phase 1b results of teclistamab in combination with DARZALEX? (daratumumab) subcutaneous (SC) also presented at ASH 2021 Annual Meeting1,2 The Janssen Pharmaceutical Companies of Johnson Johnson

Related Keywords

France ,United States ,American ,Noah Reymond ,Yusri Elsayed ,Edmond Chan Mbch ,Philippe Moreau ,Jessica Moore ,Janssen Biotech Inc ,American Society Of Hematology Annual Meeting ,American Society Of Clinical Oncology ,Cancer Research Institute ,Drugs Take Center Stage In Myeloma ,Janssen Research Development ,Janssen Pharmaceutical Companies ,Janssen Pharmaceutical Companies Of Johnson ,American Society Of Hematology ,University Hospital ,American Cancer Society ,None Of The Janssen Pharmaceutical Companies ,Drug Administration ,European Commission ,Exchange Commission ,Companies Of Johnson ,European Commission Grants Marketing Authorisation ,European Medicines Agency ,Johnson ,American Society ,Confidence Interval ,Clinical Hematology ,Vice President ,Hematologic Malignancies Disease Area Leader ,Edmond Chan ,Area Lead Haematology ,Orphan Drug Designation ,Breakthrough Therapy Designation ,Janssen Biotech ,Product Characteristics ,Pharmaceutical Companies ,Cardiovascular Metabolism ,Infectious Diseases Vaccines ,Janssen Cilag Limited ,Private Securities Litigation Reform Act ,Janssen Pharmaceutica ,Annual Report ,Note Regarding Forward Looking ,Quarterly Report ,Results From ,B Cell Maturation Antigen ,Refractory Multiple ,Hematology Annual ,Refractory Multiple Myeloma ,Escalation Study ,Participants With Relapsed ,Preclinical Activity ,Multiple Myeloma ,Clin Cancer ,Cell Therapy ,Targetingb Cell Maturation Antigen ,Potential Uses ,Targeting Drugs Take Center Stage ,Subcutaneous Daratumumab Regimens ,Participants With Multiple ,Accessed December ,Combination With Daratumumab Subcutaneously ,Versus Daratumumab ,Serious Conditions ,Commission Grants Marketing Authorisation ,Subcutaneous Formulation ,Dexamethasone Versus Bortezomib ,Patients With Previously Treated Multiple Myeloma ,Three Year Follow Up ,Lymphoma Myeloma ,Today Population Factsheets ,Janssen ,Data ,Rom ,Ajestec ,Study ,Show ,Ontinued ,Jeep ,Durable ,Responses ,Teclistamab ,Cmaxcd3 ,Bispecific ,Ntibody ,Treatment ,Heavily ,Reated ,Patients ,Multiple ,Myeloma ,